Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05706909
Other study ID # 22-580
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 8, 2023
Est. completion date July 2027

Study information

Verified date April 2024
Source The Cleveland Clinic
Contact Alison Klika
Phone 216-444-4954
Email klikaa@ccf.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to assess the clinical and x-ray results of patients who are treated with core decompression of the hip and the injection of a bone marrow concentrate and the use of the Bone Graft Substitute Genex®.


Description:

Avascular necrosis (AVN) or osteonecrosis (ON) of the femoral head refers to a condition in bone metabolism when cells of the trabecular bone (porous bone found at the end of long bones like the femur) in the hip spontaneously die. Depending on the amount of femoral head involvement, parts of the surface, like the articular surface that do not have blood vessels may collapse as the disease advances. Although the exact common occurrence of AVN or ON is unknown, the incidence is estimated to be between 20,000 to 30,000 newly diagnosed patients each year in the US. Core decompression of the hip is a minimally invasive surgical technique performed to manage symptoms in early stages (precollapse) of the condition. The procedure involves drilling holes into the femoral head to relieve pressure and create channels for new blood vessels to nourish the affected areas. Multiple adjuncts to core decompression, such as structural bone grafts, bone marrow concentrates, and bone proteins have been developed to accelerate the healing process in these patients. In recent years, considerable research activity has also been expanded to find new bone substitutes with osteoconductive properties (where bone grows on a surface) for the use in the treatment of surgically created defects. Genex® Bone Graft Substitute is a catalyst for bone healing. It complements the body's natural healing processes and encourages normal bone structure to be restored at a steady rate. Over 12 months, the graft matrix is completely absorbed and replaced by bone. No foreign artifacts are left behind to impair structural integrity.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date July 2027
Est. primary completion date February 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject is at least 18 years or older with osteonecrosis of the femoral head - Surgeon considers the patient appropriate for the core decompression procedure of the hip - Subject provides voluntarily signature on the IRB approved Informed Consent Form - Subject must be physically and mentally willing and able, in the Investigator's opinion at the time of enrollment, to be compliant with the protocol and complete the study protocol and follow ups Exclusion Criteria: - Subject is pregnant at the time of surgery - Subject is incarcerated - Subject is not comfortable with speaking, reading and understanding questions and providing responses in an available language for the questionnaires provided for the study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Genex with ABMC
Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio

Sponsors (2)

Lead Sponsor Collaborator
The Cleveland Clinic Biocomposites Ltd

Country where clinical trial is conducted

United States, 

References & Publications (3)

Moya-Angeler J, Gianakos AL, Villa JC, Ni A, Lane JM. Current concepts on osteonecrosis of the femoral head. World J Orthop. 2015 Sep 18;6(8):590-601. doi: 10.5312/wjo.v6.i8.590. eCollection 2015 Sep 18. — View Citation

Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012 Apr;41(2):183-90. doi: 10.1007/s12020-011-9580-0. Epub 2011 Dec 15. — View Citation

Yang HL, Zhu XS, Chen L, Chen CM, Mangham DC, Coulton LA, Aiken SS. Bone healing response to a synthetic calcium sulfate/beta-tricalcium phosphate graft material in a sheep vertebral body defect model. J Biomed Mater Res B Appl Biomater. 2012 Oct;100(7):1911-21. doi: 10.1002/jbm.b.32758. Epub 2012 Jul 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline X-ray result. Assessment of bone regeneration 6 weeks, 12 weeks, 6 months, 12 months post operatively
Primary Change from baseline MRI result. Assessment for no further collapse or progression of osteonecrosis 12 months
Secondary Numeric Pain Scale To assess pain using the Numeric Pain Scale on a scale of 0-10 with 10 being the worst possible pain report and 0 being no pain Baseline, 6 weeks, 12 weeks, 6 months, 12 months
Secondary Modified Harris Hip Score To evaluate the success of the core decompression procedure using the Modified Harris Hip Score by adding up the assigned points for each question, divided by a maximum score of (91) x 100 to create a percentage. A higher score equals a higher level of physical function (100% = full function). Baseline, 6 weeks, 12 weeks, 6 months, 12 months
Secondary Hip Outcome Score To assess the outcome of the treatment intervention using the Hip Outcome Score with five possible responses, graded from 0 to 4 with 4 being no difficulty at all and 0 unable to do in regard to physical limitations. Baseline, 6 weeks, 12 weeks, 6 months, 12 months
Secondary EQ-5D-5L Score To assess aspects of mobility, self-care, usual activities, pain/discomfort and anxiety/depression using the EQ-5D-5L tool. The EQ-5D-5L descriptive system uses (1) 'not /no problems', (2) 'slight problems', (3) 'moderate problems', (4) 'severe problems', and (5) 'unable to' (mobility, self-care, usual activities), 'extreme' (pain/depression), or 'extremely' (anxiety/depression). Baseline, 6 weeks, 12 weeks, 6 months, 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03312465 - Anatomical Shoulder Domelock System Study
Completed NCT02139345 - TC-A Registration Study N/A
Completed NCT03540030 - Opioid-Free Shoulder Arthroplasty Phase 4
Completed NCT01285843 - Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component N/A
Completed NCT00750984 - A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing N/A
Active, not recruiting NCT00175487 - Comparison of Hip Resurfacing to Large Femoral Head Total Hip Arthroplasty N/A
Terminated NCT00872547 - Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement Phase 4
Completed NCT00603395 - A Prospective Clinical Study On A Total Hip Resurfacing System N/A
Recruiting NCT02503891 - AL-2 MP-1 (Polyimide) Acetabular Liner N/A
Completed NCT03666637 - Femoral Neck Fracture in Adult and Avascular Necrosis and Nonunion
Active, not recruiting NCT03343171 - Continuum Ceramic on Ceramic Bearing Post Market Clinical Follow-Up Study
Enrolling by invitation NCT05067543 - Perform Humeral System Study
Recruiting NCT05002335 - Clinical and Radiological Outcomes of Medacta Shoulder System (BE)
Active, not recruiting NCT03423953 - Comprehensive Nano - Post Market Clinical Follow-Up Study
Active, not recruiting NCT05049993 - Pyrocarbon Clinical Follow-up Study
Completed NCT02162186 - Clinical and Radiographic Outcomes of the Corin Tri-Fit Total Hip Replacement
Active, not recruiting NCT01700543 - Sidus(TM) Post Market Clinical Follow-up (PMCF) Study
Active, not recruiting NCT02199600 - The Medacta International GMK Sphere Post-Marketing Surveillance Study N/A
Not yet recruiting NCT01437124 - Metal Ions in Ceramic on Metal Total Hip Arthroplasty N/A
Terminated NCT00764959 - Retrospective Study of the Linear™ Hip Phase 4